Opportunities for <i>Helicobacter pylori</i> Eradication beyond Conventional Antibiotics
<i>Helicobacter pylori</i> (<i>H. pylori</i>) is a bacterium known to be associated with a significant risk of gastric cancer in addition to chronic gastritis, peptic ulcer, and MALT lymphoma. Although only a small percentage of patients infected with <i>H. pylori</i...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-09-01
|
| Series: | Microorganisms |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-2607/12/10/1986 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850205523246317568 |
|---|---|
| author | Camilia Metadea Aji Savitri Kartika Afrida Fauzia Ricky Indra Alfaray Hafeza Aftab Ari Fahrial Syam Masrul Lubis Yoshio Yamaoka Muhammad Miftahussurur |
| author_facet | Camilia Metadea Aji Savitri Kartika Afrida Fauzia Ricky Indra Alfaray Hafeza Aftab Ari Fahrial Syam Masrul Lubis Yoshio Yamaoka Muhammad Miftahussurur |
| author_sort | Camilia Metadea Aji Savitri |
| collection | DOAJ |
| description | <i>Helicobacter pylori</i> (<i>H. pylori</i>) is a bacterium known to be associated with a significant risk of gastric cancer in addition to chronic gastritis, peptic ulcer, and MALT lymphoma. Although only a small percentage of patients infected with <i>H. pylori</i> develop gastric cancer, Gastric cancer causes more than 750,000 deaths worldwide, with 90% of cases being caused by <i>H. pylori.</i> The eradication of this bacterium rests on multiple drug regimens as guided by various consensus. However, the efficacy of empirical therapy is decreasing due to antimicrobial resistance. In addition, biofilm formation complicates eradication. As the search for new antibiotics lags behind the bacterium’s ability to mutate, studies have been directed toward finding new anti-<i>H. pylori</i> agents while also optimizing current drug functions. Targeting biofilm, repurposing outer membrane vesicles that were initially a virulence factor of the bacteria, phage therapy, probiotics, and the construction of nanoparticles might be able to complement or even be alternatives for <i>H. pylori</i> treatment. This review aims to present reports on various compounds, either new or combined with current antibiotics, and their pathways to counteract <i>H. pylori</i> resistance. |
| format | Article |
| id | doaj-art-0da45525877f4d21b5b4d9c7e4b4aacb |
| institution | OA Journals |
| issn | 2076-2607 |
| language | English |
| publishDate | 2024-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Microorganisms |
| spelling | doaj-art-0da45525877f4d21b5b4d9c7e4b4aacb2025-08-20T02:11:04ZengMDPI AGMicroorganisms2076-26072024-09-011210198610.3390/microorganisms12101986Opportunities for <i>Helicobacter pylori</i> Eradication beyond Conventional AntibioticsCamilia Metadea Aji Savitri0Kartika Afrida Fauzia1Ricky Indra Alfaray2Hafeza Aftab3Ari Fahrial Syam4Masrul Lubis5Yoshio Yamaoka6Muhammad Miftahussurur7Department of Environmental and Preventive Medicine, Faculty of Medicine, Oita University, Yufu 879-5593, Oita, JapanHelicobacter Pylori and Microbiota Study Group, Institute of Tropical Disease, Universitas Airlangga, Surabaya 60286, IndonesiaDepartment of Environmental and Preventive Medicine, Faculty of Medicine, Oita University, Yufu 879-5593, Oita, JapanDepartment of Gastroenterology, Dhaka Medical College and Hospital, Dhaka 1000, BangladeshDivision of Gastroenterology-Hepatology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, IndonesiaDivision of Gastroenterology-Hepatology, Department of Internal Medicine, Faculty of Medicine, Universitas Sumatera Utara, Medan 20155, IndonesiaDepartment of Environmental and Preventive Medicine, Faculty of Medicine, Oita University, Yufu 879-5593, Oita, JapanHelicobacter Pylori and Microbiota Study Group, Institute of Tropical Disease, Universitas Airlangga, Surabaya 60286, Indonesia<i>Helicobacter pylori</i> (<i>H. pylori</i>) is a bacterium known to be associated with a significant risk of gastric cancer in addition to chronic gastritis, peptic ulcer, and MALT lymphoma. Although only a small percentage of patients infected with <i>H. pylori</i> develop gastric cancer, Gastric cancer causes more than 750,000 deaths worldwide, with 90% of cases being caused by <i>H. pylori.</i> The eradication of this bacterium rests on multiple drug regimens as guided by various consensus. However, the efficacy of empirical therapy is decreasing due to antimicrobial resistance. In addition, biofilm formation complicates eradication. As the search for new antibiotics lags behind the bacterium’s ability to mutate, studies have been directed toward finding new anti-<i>H. pylori</i> agents while also optimizing current drug functions. Targeting biofilm, repurposing outer membrane vesicles that were initially a virulence factor of the bacteria, phage therapy, probiotics, and the construction of nanoparticles might be able to complement or even be alternatives for <i>H. pylori</i> treatment. This review aims to present reports on various compounds, either new or combined with current antibiotics, and their pathways to counteract <i>H. pylori</i> resistance.https://www.mdpi.com/2076-2607/12/10/1986antimicrobial resistance<i>Helicobacter pylori</i>eradicationbiofilmouter membrane vesiclephage |
| spellingShingle | Camilia Metadea Aji Savitri Kartika Afrida Fauzia Ricky Indra Alfaray Hafeza Aftab Ari Fahrial Syam Masrul Lubis Yoshio Yamaoka Muhammad Miftahussurur Opportunities for <i>Helicobacter pylori</i> Eradication beyond Conventional Antibiotics Microorganisms antimicrobial resistance <i>Helicobacter pylori</i> eradication biofilm outer membrane vesicle phage |
| title | Opportunities for <i>Helicobacter pylori</i> Eradication beyond Conventional Antibiotics |
| title_full | Opportunities for <i>Helicobacter pylori</i> Eradication beyond Conventional Antibiotics |
| title_fullStr | Opportunities for <i>Helicobacter pylori</i> Eradication beyond Conventional Antibiotics |
| title_full_unstemmed | Opportunities for <i>Helicobacter pylori</i> Eradication beyond Conventional Antibiotics |
| title_short | Opportunities for <i>Helicobacter pylori</i> Eradication beyond Conventional Antibiotics |
| title_sort | opportunities for i helicobacter pylori i eradication beyond conventional antibiotics |
| topic | antimicrobial resistance <i>Helicobacter pylori</i> eradication biofilm outer membrane vesicle phage |
| url | https://www.mdpi.com/2076-2607/12/10/1986 |
| work_keys_str_mv | AT camiliametadeaajisavitri opportunitiesforihelicobacterpyloriieradicationbeyondconventionalantibiotics AT kartikaafridafauzia opportunitiesforihelicobacterpyloriieradicationbeyondconventionalantibiotics AT rickyindraalfaray opportunitiesforihelicobacterpyloriieradicationbeyondconventionalantibiotics AT hafezaaftab opportunitiesforihelicobacterpyloriieradicationbeyondconventionalantibiotics AT arifahrialsyam opportunitiesforihelicobacterpyloriieradicationbeyondconventionalantibiotics AT masrullubis opportunitiesforihelicobacterpyloriieradicationbeyondconventionalantibiotics AT yoshioyamaoka opportunitiesforihelicobacterpyloriieradicationbeyondconventionalantibiotics AT muhammadmiftahussurur opportunitiesforihelicobacterpyloriieradicationbeyondconventionalantibiotics |